阿尔及利亚庞贝病临床分析。

Journal of Neurodegenerative Diseases Pub Date : 2017-01-01 Epub Date: 2017-02-06 DOI:10.1155/2017/9427269
Y Sifi, M Medjroubi, R Froissart, N Taghane, K Sifi, A Benhabiles, S Lemai, S Semra, H Benmekhebi, Z Bouderda, N Abadi, A Hamri
{"title":"阿尔及利亚庞贝病临床分析。","authors":"Y Sifi,&nbsp;M Medjroubi,&nbsp;R Froissart,&nbsp;N Taghane,&nbsp;K Sifi,&nbsp;A Benhabiles,&nbsp;S Lemai,&nbsp;S Semra,&nbsp;H Benmekhebi,&nbsp;Z Bouderda,&nbsp;N Abadi,&nbsp;A Hamri","doi":"10.1155/2017/9427269","DOIUrl":null,"url":null,"abstract":"<p><p>Pompe's disease is a metabolic myopathy caused by a deficiency of acid alpha-glucosidase (GAA), also called acid maltase, an enzyme that degrades lysosomal glycogen. The clinical presentation of Pompe's disease is variable with respect to the age of onset and rate of disease progression. Patients with onset of symptoms in early infancy (infantile-onset Pompe disease (IOPD)) typically exhibit rapidly progressive hypertrophic cardiomyopathy and marked muscle weakness. Most of them die within the first year of life from cardiac and/or respiratory failure. In the majority of cases of Pompe's disease, onset of symptoms occurs after infancy, ranging widely from the first to sixth decade of life (late-onset Pompe's disease or LOPD). Progression of the disease is relentless and patients eventually progress to loss of ambulation and death due to respiratory failure. The objective of this study was to characterize the clinical presentation of 6 patients (3 with EOPD and the other 3 with LOPD) of 5 families from the East of Algeria. All our patients were diagnosed as having Pompe's disease based on biochemical confirmations of GAA deficiency by dried blood spots (DBS) and GAA gene mutations were analyzed in all patients who consented (<i>n</i> = 4). Our results are similar to other ethnic groups.</p>","PeriodicalId":16405,"journal":{"name":"Journal of Neurodegenerative Diseases","volume":"2017 ","pages":"9427269"},"PeriodicalIF":0.0000,"publicationDate":"2017-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2017/9427269","citationCount":"3","resultStr":"{\"title\":\"Clinical Analysis of Algerian Patients with Pompe Disease.\",\"authors\":\"Y Sifi,&nbsp;M Medjroubi,&nbsp;R Froissart,&nbsp;N Taghane,&nbsp;K Sifi,&nbsp;A Benhabiles,&nbsp;S Lemai,&nbsp;S Semra,&nbsp;H Benmekhebi,&nbsp;Z Bouderda,&nbsp;N Abadi,&nbsp;A Hamri\",\"doi\":\"10.1155/2017/9427269\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Pompe's disease is a metabolic myopathy caused by a deficiency of acid alpha-glucosidase (GAA), also called acid maltase, an enzyme that degrades lysosomal glycogen. The clinical presentation of Pompe's disease is variable with respect to the age of onset and rate of disease progression. Patients with onset of symptoms in early infancy (infantile-onset Pompe disease (IOPD)) typically exhibit rapidly progressive hypertrophic cardiomyopathy and marked muscle weakness. Most of them die within the first year of life from cardiac and/or respiratory failure. In the majority of cases of Pompe's disease, onset of symptoms occurs after infancy, ranging widely from the first to sixth decade of life (late-onset Pompe's disease or LOPD). Progression of the disease is relentless and patients eventually progress to loss of ambulation and death due to respiratory failure. The objective of this study was to characterize the clinical presentation of 6 patients (3 with EOPD and the other 3 with LOPD) of 5 families from the East of Algeria. All our patients were diagnosed as having Pompe's disease based on biochemical confirmations of GAA deficiency by dried blood spots (DBS) and GAA gene mutations were analyzed in all patients who consented (<i>n</i> = 4). Our results are similar to other ethnic groups.</p>\",\"PeriodicalId\":16405,\"journal\":{\"name\":\"Journal of Neurodegenerative Diseases\",\"volume\":\"2017 \",\"pages\":\"9427269\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2017-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1155/2017/9427269\",\"citationCount\":\"3\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Neurodegenerative Diseases\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1155/2017/9427269\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2017/2/6 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Neurodegenerative Diseases","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1155/2017/9427269","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2017/2/6 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 3

摘要

庞贝氏病是一种由酸性α -葡萄糖苷酶(GAA)缺乏引起的代谢性肌病,也称为酸性麦芽糖酶,一种降解溶酶体糖原的酶。庞贝氏病的临床表现与发病年龄和疾病进展速度有关。婴儿期早期发病的患者(婴儿型庞贝病(IOPD))通常表现为快速进行性肥厚性心肌病和明显的肌肉无力。他们中的大多数在出生后一年内死于心脏和/或呼吸衰竭。在大多数庞贝氏病病例中,症状发生在婴儿期之后,范围广泛,从生命的第一个到第六个十年(迟发性庞贝氏病或LOPD)。疾病的进展是无情的,患者最终进展到行动不便和死亡,由于呼吸衰竭。本研究的目的是描述来自阿尔及利亚东部5个家庭的6例患者(3例EOPD, 3例LOPD)的临床表现。我们所有的患者都被诊断为Pompe病,基于干血斑(DBS)生化证实GAA缺乏,并分析所有同意的患者的GAA基因突变(n = 4)。我们的结果与其他种族相似。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

Clinical Analysis of Algerian Patients with Pompe Disease.

Clinical Analysis of Algerian Patients with Pompe Disease.

Pompe's disease is a metabolic myopathy caused by a deficiency of acid alpha-glucosidase (GAA), also called acid maltase, an enzyme that degrades lysosomal glycogen. The clinical presentation of Pompe's disease is variable with respect to the age of onset and rate of disease progression. Patients with onset of symptoms in early infancy (infantile-onset Pompe disease (IOPD)) typically exhibit rapidly progressive hypertrophic cardiomyopathy and marked muscle weakness. Most of them die within the first year of life from cardiac and/or respiratory failure. In the majority of cases of Pompe's disease, onset of symptoms occurs after infancy, ranging widely from the first to sixth decade of life (late-onset Pompe's disease or LOPD). Progression of the disease is relentless and patients eventually progress to loss of ambulation and death due to respiratory failure. The objective of this study was to characterize the clinical presentation of 6 patients (3 with EOPD and the other 3 with LOPD) of 5 families from the East of Algeria. All our patients were diagnosed as having Pompe's disease based on biochemical confirmations of GAA deficiency by dried blood spots (DBS) and GAA gene mutations were analyzed in all patients who consented (n = 4). Our results are similar to other ethnic groups.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信